Young K. Chen,Toufike Kanouni,Stephen W. Kaldor,Jeffrey Alan Stafford,James Marvin Veal,Paula Alessandra Tavares-Greco,Matthew Michael Kreilein
申请号：
US15793512
公开号：
US10047069B2
申请日:
2017.10.25
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
